The clinical research on early diabetic nephropathy treated with Fufang-Xueshuantong capsule

Abstract

Objective To observe the clinical effect of early diabetic nephropathy treated with Fufang-Xueshuantong capsule. Methods 90 hospitalized patients from September 2011 to October 2012 with early diabetic nephropathy were recruited in Shangqiu First people＇s hospital endocrinology of Henan Province. All patients were divided into two groups randomly, with 45 patients in each group. The control group was treated with diabetes education, blood glucose control, blood pressure control, and blood lipid regulation, while the treatment group was treated with Fufang-Xueshantong capsule on the basis of the control group. The change of blood glucose, HbA1c, urine microalbumin, and Ualb/Cr were measured before and 12 weeks after the treatment. Results ① Compared the urine microalbumin, Ualb/Cr of the two groups before and after treatment：the urine microalbumin, Ualb/Cr of the two groups after the treatment [Treatment group was（24.5±9.1）mg/L,（2.4± 1.6）mg/mmol, Control group was（85.9±8.6）mg/L,（5.6±2.1）mg/mmol] were significantly reduced than before the treatment （P〈0.01 or 0.05）[Treatment group was （142.5±20.8）mg/L, （27.1±5.3）mg/mmol, Control group was （141.6±21.6）mg/L, （26.3±5.64）mg/mmol], while the effect of treatment group was better than control group（P〈0.05）. ② Compared the FBG, 2 hBG, HbA1c of the two groups before and after treatment：After treatment the level of FBG, 2 hBG, HbA1c of the two groups [Treatment group was（5.58±1.57）mmol/L,（7.82±2.43）mmol/L, （7.01± 1.22）%, Control group was（5.67 ± 1.46）mmol/L,（7.71 ± 2.59）mmol/L,（6.83 ± 2.31）%]were also reduced than before（P〈0.05）. [Treatment group was （8.69±1.59）mmol/L,（12.79±2.50）mmol/L,（9.91±1.98）%, Control group was（8.72±1.56）mmol/L, （12.86±2.25）mmol/L,（9.89±2.03）%], but there was no statistically difference between the groups（P>0.05）. Conclusion Fufang-Xueshuantong capsule had good effect in treating early diabetic nephropathy, it can also delay the progress of renal damage. Key words: Fufang-Xueshuantong capsule; Diabetic nephropathy; Therapeutic effect analysis